Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

600

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV-1-Infection

Interventions

DRUG: ISL/LEN
DRUG: Antiretroviral Combinations

Sponsor

Gilead Sciences

Collaborators

[object Object]